Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer ' s Disease

NEW YORK, Dec. 16, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ( " Synaptogenix " or the " Company " ), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced topline...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials